TUDCA (Tauroursodeoxycholic Acid)
TUDCA is a taurine-conjugated bile acid with a narrow but defensible liver, bile-flow, and metabolic role; Kars 2010 reported roughly 30% better hepatic and skeletal-muscle insulin sensitivity after 4 weeks in obese T2D. The ALS combination-drug story weakened after Amylyx PHOENIX failed in 2024.
TUDCA (Tauroursodeoxycholic Acid) scored 5.8 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Exogenous Metabolite.
What It Is
TUDCA (Tauroursodeoxycholic Acid) scores 5.8/10 because its strongest case is hepatobiliary, bile-acid, insulin-sensitivity, and carefully framed neuroprotection contexts, with weaker support outside that lane. The best read is practical and narrow: match the intervention to readers targeting liver, bile-flow, or metabolic questions with medical monitoring.
The main evidence anchor is Kars et al. 2010. Pan et al. 2013 adds important context, while Elia et al. 2016 helps define the safety, sourcing, or regulatory caveat that keeps the score from moving higher.
The key caveat is that the ALS story became mixed after AMX0035 failed in Phase III, and UDCA evidence cannot be treated as identical to TUDCA evidence. This report treats TUDCA as a candidate for specific use cases, not a general wellness shortcut.
Terminology
AMPA: A glutamate receptor family involved in fast excitatory signaling. - CYP1A2: A liver enzyme relevant to caffeine and xanthine metabolism. - ER Stress: Endoplasmic-reticulum stress, a cellular protein-folding stress pathway. - MAO-B: Monoamine oxidase B, an enzyme that breaks down dopamine-related monoamines. - NOAEL: No observed adverse effect level in toxicology work.
UDCA: Ursodeoxycholic acid, the unconjugated parent bile acid of TUDCA. - WADA: World Anti-Doping Agency, relevant for athlete prohibited-list risk.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Capsule, powder, tablet, or food form depending on intervention | 250-1,000 mg/day in supplement use; higher supervised ranges appear in ALS studies | 250-1,000 mg/day in supplement use; higher supervised ranges appear in ALS studies |
Protocols
Conservative research comparison Mixed
- Dose
- 500-1,750 mg
- Frequency
- As studied or label-directed, with outcome tracking
- Duration
- Single session to 12 weeks depending on endpoint
Research-assistance framing only; avoid unsupervised escalation.
How this score is calculated →
Upside contribution: 1.61
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.8 | 0.700 | |
| Breadth of Benefits | 15% | 3.0 | 0.450 | |
| Evidence Quality | 25% | 2.6 | 0.650 | |
| Speed of Onset | 10% | 2.0 | 0.200 | |
| Durability | 10% | 2.5 | 0.250 | |
| Bioindividuality Upside | 15% | 2.4 | 0.360 | |
| Total | 2.610 |
Upside Rationale
TUDCA (Tauroursodeoxycholic Acid) scores 5.8/10 because its upside is concentrated in hepatobiliary, bile-acid, insulin-sensitivity, and carefully framed neuroprotection contexts. The clearest anchor is a small insulin-sensitivity study, liver trials, and ALS add-on evidence with later combination-drug caveats, so the rating rewards the specific use cases while staying conservative about claims beyond them.
Efficacy (3.5/5.0): TUDCA earns this efficacy score because the best signals map to hepatobiliary, bile-acid, insulin-sensitivity, and carefully framed neuroprotection contexts. Kars et al. 2010 is the main anchor, while Pan et al. 2013 helps define where the signal remains preliminary.
Breadth of Benefits (3.4/5.0): TUDCA has limited breadth outside its core lane. The report gives more credit where the evidence matches readers targeting liver, bile-flow, or metabolic questions with medical monitoring, and less where endpoints drift into unrelated systems.
Evidence Quality (3.1/5.0): TUDCA evidence quality is constrained by sample size, age of the literature, sponsor concentration, or indirect endpoints. Kars et al. 2010 and Elia et al. 2016 keep the score useful without overstating certainty.
Speed of Onset (2.8/5.0): TUDCA can produce faster feedback when the intended effect is acute attention, energy, sleep timing, digestion, or performance. That speed helps users judge fit, but it does not replace longer safety follow-up.
Durability (3.0/5.0): TUDCA durability is moderate to low when continued dosing, training context, sleep timing, diet, or supply quality drives the result. The score rises only when the benefit can be maintained without chasing dose escalation.
Bioindividuality Upside (3.2/5.0): TUDCA has meaningful bioindividuality because baseline need, medications, caffeine response, training status, liver or bile context, sleep pressure, and tolerance can change the outcome. Pan et al. 2013 is useful for defining that context.
Downside contribution: 0.79 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.8 | 0.540 | |
| Side Effect Profile | 15% | 1.6 | 0.240 | |
| Financial Cost | 5% | 2.2 | 0.110 | |
| Time/Effort Burden | 5% | 1.4 | 0.070 | |
| Opportunity Cost | 5% | 1.8 | 0.090 | |
| Dependency / Withdrawal | 15% | 1.3 | 0.195 | |
| Reversibility | 25% | 1.4 | 0.350 | |
| Total | 1.595 | |||
| Harm subtotal × 1.4 | 1.855 | |||
| Opportunity subtotal × 1.0 | 0.270 | |||
| Combined downside | 2.125 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.785 |
Downside Rationale
TUDCA also needs a specific Relyvrio caveat. Taurursodiol was the bile-acid component of Amylyx's AMX0035, branded Relyvrio in the United States and Albrioza in Canada. CENTAUR was positive on ALSFRS-R slope, but the larger 2024 PHOENIX Phase III trial missed its primary endpoint and Amylyx voluntarily withdrew the product from the U.S. and Canadian markets after the PHOENIX result Amylyx 2024. That does not erase TUDCA's separate metabolic and hepatobiliary evidence, but it materially weakens the ALS extrapolation.
Verdict
TUDCA is a conditional research candidate rather than a universal recommendation. The score is most favorable when the reader's target matches the highest use-case scores, the product source is credible, and the reader can track a concrete outcome before and after use. The score is least favorable when TUDCA is used to chase vague optimization, replace higher-certainty basics, or stack with overlapping compounds without a clear reason.
✅ Best for: Liver, bile-flow, insulin-sensitivity, or neuroprotection research where TUDCA is kept distinct from UDCA. TUDCA makes the most sense when the reader can define the target outcome in advance, compare TUDCA with the related reports above, and stop quickly if the result is poor.
❌ Avoid if: Avoid TUDCA when legal status, athlete testing, medication conflicts, allergy risk, organ disease, pregnancy questions, stimulant sensitivity, or poor sourcing changes the risk picture. Avoid using TUDCA as a substitute for sleep, nutrition, training, medical care, or well-supported alternatives. The ALS use case deserves extra caution: AMX0035/Relyvrio combined taurursodiol with sodium phenylbutyrate, PHOENIX failed in 2024, and Amylyx withdrew the product from the U.S. and Canadian markets. Avoid treating old ALS optimism as proof that stand-alone TUDCA is neuroprotective for healthy users.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Liver / Detoxification: 6.5/10
Score: 6.5/10TUDCA scores 6.5/10 for liver detox because the most direct human evidence concerns hepatobiliary disease, bile acids, and liver-related endpoints rather than vague detox language. Pan 2013 studied TUDCA in liver cirrhosis, and Larghi 1997 provides PBC crossover context for TUDCA and UDCA. This is the strongest use-case lane, but the report still discounts the score when supplement marketing turns clinical hepatology evidence into unspecific organ-cleanse claims.
Gut Health / Microbiome: 5.8/10
Score: 5.8/10TUDCA scores 5.8/10 for gut health because bile-acid physiology makes digestive tolerance and bile-flow questions plausible, but direct wellness evidence is still narrow. The strongest relevant clinical context comes from Larghi 1997 in PBC and Pan 2013 in liver cirrhosis, not from the unrelated Albrecht 1991 dental paper. For readers, TUDCA is best interpreted as a hepatobiliary-adjacent candidate whose gut relevance depends on bile-flow symptoms, stool tolerance, and clear before-and-after tracking rather than broad microbiome claims.
Metabolic Health: 5.5/10
Score: 5.5/10TUDCA scores 5.5/10 for metabolic health because Kars 2010 gives a small but direct human insulin-sensitivity signal. In obese adults, four weeks of TUDCA improved hepatic insulin sensitivity by 30 percent and skeletal-muscle insulin sensitivity by 28 percent Kars 2010. The score stays moderate because the study was short, population-specific, and not a long-term diabetes-outcomes trial. This supports metabolic interest, not a broad glucose-management recommendation for everyone.
Blood Sugar / Glycemic Control: 5.5/10
Score: 5.5/10TUDCA scores 5.5/10 for blood sugar because the best human anchor is insulin sensitivity, not direct HbA1c or remission data. Kars 2010 found improved hepatic and skeletal-muscle insulin sensitivity after four weeks in obese adults, which is relevant but still preliminary. The practical rating stays bounded by sample size, short follow-up, and the absence of cleaner comparisons against diet, resistance training, weight loss, metformin, or other higher-certainty metabolic tools.
Neuroprotection: 5.2/10
Score: 5.2/10TUDCA scores 5.2/10 for neuroprotection because ALS evidence moved from promising to mixed. Elia 2016 reported a positive small TUDCA add-on ALS trial, and Paganoni 2020 found a Phase II signal for AMX0035, a sodium phenylbutyrate-taurursodiol combination. The larger 2024 PHOENIX trial missed its primary endpoint, and Amylyx withdrew Relyvrio/Albrioza from the U.S. and Canadian markets. That makes the ALS monotherapy story substantially weaker than 2016-2020 enthusiasm suggested.
Frequently Asked Questions
What does TUDCA actually do?
TUDCA mainly acts through the biology described in this report, and the best concise source is Albrecht M. et al. 1991. TUDCA should be read as a research-assistance topic rather than a treatment recommendation. That is why the score separates plausible pathways from proven user value.
How much TUDCA is typically used?
TUDCA is usually discussed around 250-1,000 mg/day in supplement use; higher supervised ranges appear in ALS studies, but dosing depends on context, product quality, and clinician constraints. This report lists research and anecdotal ranges for comparison only. TUDCA should not be stacked casually with overlapping drugs or stimulants, and higher doses should be treated as a separate risk decision. The safest reading is to compare published ranges with the label and personal tolerance.
What does the human evidence show for TUDCA?
TUDCA has an evidence profile led by Albrecht M. et al. 1991 and the other sources in the evidence table. TUDCA receives credit when human outcomes exist and loses credit when the work is small, industry-concentrated, disease-specific, or not independently replicated. That is why a popular community use can still receive a modest score when the direct clinical literature is thin.
Is TUDCA safe long term?
TUDCA looks safer when dose, source quality, medication conflicts, and stop criteria are handled conservatively. The long-term safety answer is weaker when human follow-up is short, when products are unapproved drugs, or when stimulant effects can affect sleep and cardiovascular comfort. TUDCA earns a better safety rating only where the evidence base includes ordinary-use tolerability and clear reversibility.
Who should avoid TUDCA?
TUDCA should be avoided by readers with relevant medication conflicts, pregnancy questions, severe organ disease, allergy risk, or athlete testing exposure when those concerns apply. TUDCA also deserves caution when the supply chain is unclear or when the main goal could be met by better-studied options. The report frames these as research guardrails, not individualized medical instructions.
How fast does TUDCA work?
TUDCA may feel acute when the mechanism is stimulant-like, but disease or recovery outcomes usually need longer observation. The timeline in this report separates same-day subjective effects from delayed biomarkers and functional changes. TUDCA should be judged with a preplanned outcome, because vague improvement tracking can make short-lived arousal feel more useful than it is.
How is TUDCA different from nearby alternatives?
TUDCA differs from nearby alternatives by mechanism, evidence quality, legality, and product reliability. The related reports linked in the verdict help compare TUDCA with better-known options before treating the category as interchangeable. A close alternative may have lower subjective novelty but better replication, easier sourcing, or fewer interaction problems, which matters for the final score.
What would make the TUDCA score change?
TUDCA would score higher with larger independent trials, longer safety follow-up, clearer dosing, and direct evidence for the main use cases. TUDCA would score lower if safety signals strengthen, product quality worsens, or better alternatives cover the same goal with less uncertainty. The score is therefore a snapshot of current evidence, not a permanent verdict.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
TUDCA could move meaningfully if the evidence base changes because several current uncertainties are fixable. Independent trials could raise confidence, longer follow-up could clarify safety, and better product testing could reduce sourcing concern. TUDCA could also fall if larger studies fail to replicate the small positive findings, if regulatory scrutiny increases, or if real-world users report a pattern of sleep, mood, digestive, or cardiovascular problems. The scenarios below show how the same intervention can move across tiers without changing the scoring method, simply by improving or weakening the underlying facts.
| Scenario | Likely score |
|---|---|
| Larger independent human trials replicate the best outcome and safety stays clean. | 7.0 / 10 💪 Strong recommend |
| Evidence stays mostly small, sponsor-linked, or disease-specific. | 5.8 / 10 👍 Worth trying |
| New safety, sourcing, regulatory, or replication concerns appear. | 4.6 / 10 ⚠️ Caution |
BioHarmony Engine v1.0
Key Evidence Sources
- Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. 2010 human metabolic study in obese adults; four weeks of TUDCA improved hepatic and skeletal-muscle insulin sensitivity, with limited sample size and short follow-up.
- Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. 2013 double-blind randomized liver-cirrhosis trial; useful hepatobiliary evidence, but not a direct NAFLD wellness trial and not proof of detox claims.
- Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. 1997 pilot crossover PBC study comparing UDCA and tauro-UDCA; cited for cholestasis context with the parent compound distinction explicit. Parent compound context is explicit because UDCA and TUDCA are not interchangeable.
- Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. 2016 small ALS add-on trial; positive signal on ALS progression but population, size, and replication limits keep neuroprotection confidence moderate.
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. 2020 CENTAUR Phase II randomized ALS trial of AMX0035; taurursodiol was combined with sodium phenylbutyrate, so it is not TUDCA monotherapy evidence. Related compound context: taurursodiol was the TUDCA-derived bile-acid component in AMX0035.
- Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. 2021 CENTAUR survival follow-up; relevant to AMX0035 context but still combination-therapy evidence with sponsor concentration. Related compound context: taurursodiol was the TUDCA-derived bile-acid component in AMX0035.
- Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS. 2024 company topline release for the 664-participant PHOENIX Phase III trial; primary and secondary endpoints were missed, weakening AMX0035 translation. Related compound context: taurursodiol was the TUDCA-derived bile-acid component in AMX0035.
- Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market. April 2024 formal withdrawal announcement after PHOENIX; cited for regulatory and trust context, not as efficacy evidence. Related compound context: taurursodiol was the TUDCA-derived bile-acid component in AMX0035.
- Tauroursodeoxycholate: bile acid with chaperoning activity, molecular and cellular effects and therapeutic perspectives. 2019 mechanistic review covering ER stress, apoptosis, inflammation, and translational limits; useful background, not primary outcome evidence.
- Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS. ClinicalTrials.gov registry for TUDCA add-on ALS research; cited as trial-context background and not used as completed positive evidence.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Kars 2010: Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Kars 2010: Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women
Traditional Medicine Systems
Citations: Tauroursodeoxycholic Acid may improve liver and muscle but not adip..., Efficacy and safety of tauroursodeoxycholic acid in the treatment o..., Tauroursodeoxycholic acid in the treatment of patients with amyotro...
Holistic Evidence for TUDCA (Tauroursodeoxycholic Acid)
TUDCA's historical bile-acid context and modern ER-stress research point in similar directions, but ALS translation remains mixed.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- ALT Baseline (pre-protocol)
- AST Post | Expected Down
- Fasting Glucose Post | Expected Down
Pulse Dimensions to Watch
- Body During | Expected Up | Primary
- Energy During | Expected Watch | Secondary
Subjective Signals (Daily Voice Card)
- Bile Flow Comfort Scale 1-5 | During | Expected Up
- Loose Stools Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Severe abdominal pain or jaundice
- Persistent diarrhea or medication interaction concerns
Other interventions for Liver Detox
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.610 − 0.785 = 0.825
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.825 / 5) × 5 = 5.8 / 10
Further learning
13+ Amazing TUDCA Benefits & Best Supplements
TUDCA is a bile acid that supports your digestion of fats and oils. But did you know it comes with benefits for longevity, your…
Powerful Oral Peptides for Gut Repair, Liver Health & Mold Recovery
Kyal Van Der Leest of LVLUP Health explains BPC-157 arginate absorption, toxic mold recovery protocols, NACET vs NAC for liver support, and DHM dosing…
